Numerous studies have demonstrated elevated levels of inflammatory mediators (i.e., C-reactive protein, IL-6, and TNF-α) in patients with IHD [4–6]. Clinical trials have exhibited that anti-inflammatory agents, such as monoclonal antibodies against IL-1β, can reduce the risk of cardiovascular events in IHD patients [7]. The gene discussed is IL6; the disease is myocardial ischemia.